**Lupin Launches Authorized Generic of Ravicti Oral Liquid in the U.S. Market**

**Mumbai, October 24, 2025:** Pharma major **Lupin Limited** (BSE: 500257, NSE: LUPIN) announced the launch of an **authorized generic version of Ravicti® (Glycerol Phenylbutyrate Oral Liquid, 1.1 gm/mL)** in the **United States**, expanding its specialty product portfolio in the rare disease segment. The product is indicated for the **chronic management of patients with urea cycle disorders (UCDs)** who cannot be adequately managed by dietary protein restriction and/or amino acid supplementation alone. The launch marks an important step in strengthening Lupin’s U.S. generics business by addressing niche therapeutic areas with limited treatment options. **Ravicti®** is a registered trademark of **Horizon Therapeutics U.S. Holding LLC**, a subsidiary of **Amgen Inc.** Lupin’s version has been launched as an **authorized generic**, ensuring the same formulation and quality as the branded product while offering a more affordable treatment alternative. Headquartered in Mumbai, Lupin is a global pharmaceutical company with operations in over **100 markets** across the world. The company operates **15 manufacturing facilities** and **7 research centers**, supported by a workforce of over **24,000 employees**. Its diversified portfolio spans **branded and generic formulations, complex generics, biotechnology products, and APIs**. The disclosure was filed with the stock exchanges under **SEBI Regulation 30** and digitally signed by **Amit Kumar Gupta**, Company Secretary & Compliance Officer of Lupin Limited. **Disclaimer:** This article is for informational purposes only and not a recommendation to buy or sell securities.